Theranos

Theranos promised a revolution in medicine: cheap, quick blood tests from a finger prick, available in everyday commercial outlets instead of hospital labs.^[1] It was founded in 2003 by Elizabeth Holmes, then a student at Stanford University, who cast herself as a visionary willing to upend an ossified diagnostics industry.^[2]

For a time, the world believed her. Theranos was valued at as much as $9 billion before it collapsed amid scandal and fraud.^[2] A Library of Congress entry would later describe it as a multibillion‑dollar Silicon Valley startup that collapsed in 2017.^[3]

Holmes, as founder and CEO of the blood‑testing company, sold an irresistible narrative: with just a drop of blood, Theranos’ technology could instantly test for many medical conditions.^[2] Two former U.S. senators and former Secretary of State Henry Kissinger sat on its board, a roster that suggested gravitas and legitimacy.^[2]

Behind the scenes, the machine at the center of the story was far less miraculous than advertised.

On March 14, 2018, the U.S. Securities and Exchange Commission charged Theranos Inc., Elizabeth Holmes, and former president Ramesh “Sunny” Balwani with raising more than $700 million from investors through fraud.^[3] The SEC alleged that they exaggerated or made false statements about the company’s technology, business, and financial performance.^[3]

At the heart of the SEC complaints was the core technology. Regulators said Theranos’ proprietary analyzer could actually complete only a small number of the tests the company claimed it could run.^[3] Instead, according to the complaints, Theranos conducted the vast majority of patient tests on modified, industry‑standard commercial analyzers manufactured by others.^[3]

The agency also focused on specific stories Theranos allegedly told investors and partners. According to the SEC, Theranos, Holmes, and Balwani claimed that the company’s products were deployed by the U.S. Department of Defense on the battlefield in Afghanistan and on medevac helicopters.^[3] The SEC flatly stated that Theranos’ technology was never deployed by the Department of Defense.^[3]

Money was another fault line. The complaints alleged that Theranos told investors it would generate more than $100 million in revenue in 2014.^[3] In fact, the SEC said, the company generated a little more than $100,000 in revenue from operations that year.^[3]

By the time the charges went public, Theranos’ stunning rise had curdled into a stark example of how a grand narrative can slide into alleged deception.

In announcing the case, Steven Peikin, Co‑Director of the SEC’s Enforcement Division, was quoted criticizing the alleged fraud involving Theranos.^[3] His fellow Co‑Director, Stephanie Avakian, described the remedies the agency sought against Holmes: stripping her of control over the company, forcing her to return shares, and imposing a 10‑year bar on serving as an officer or director of a public company.^[3]

Jina Choi, Director of the SEC’s San Francisco office, used the moment to speak to the broader tech community. She warned innovators that they must tell investors the truth about what their technology can do today—not just what they hope it might achieve in the future.^[3]

In the SEC’s telling, Theranos wasn’t simply a failed startup. It was an object lesson in the dangers of letting ambition outrun honesty.

The SEC’s charges against Theranos, Holmes, and Balwani put the company’s leaders on diverging legal paths.

Holmes agreed to settle the fraud charges the SEC had levied against her and Theranos.^[3] As part of that settlement, she agreed to return the remaining 18.9 million shares she had obtained during the period the SEC described as fraudulent.^[3] She also agreed to relinquish her voting control of Theranos by converting her super‑majority Class B common shares into Class A common shares.^[3]

Because of the company’s liquidation preferences, the SEC said that if Theranos were acquired or liquidated, Holmes would not profit from her ownership until more than $750 million had been returned to defrauded investors and other preferred shareholders, assuming redemption of certain warrants.^[3] The settlements with Theranos and Holmes were subject to court approval.^[3]

Balwani, by contrast, did not resolve the case at that point. The SEC announced it would litigate its claims against him in federal district court in the Northern District of California.^[3]

Theranos’ downfall is often framed as a story about money: a startup once valued at up to $9 billion, investors allegedly defrauded of more than $700 million, a founder who lost control of her shares and her freedom.^[2][3]

But its legacy runs deeper. In clinical circles, Theranos has become shorthand for “stealth research”—high‑stakes biomedical innovation that happens largely outside peer‑reviewed science.^[4] The medical opinion paper that dissected the company’s technology did more than question its claims; it highlighted how direct‑to‑consumer, low‑volume testing could encourage people to test themselves, interpret their own results, and fall into cycles of over‑testing, over‑diagnosis, and over‑treatment.^[1]

The SEC’s enforcement leaders used the case to send a clear message: ambitious technology companies cannot paper over present limitations with future promises when money and lives are at stake.^[3]

Today, “Theranos (Firm)” lives on as an authority entry in the Library of Congress and as a subject of medical and legal commentary, its corporate name linked to works with titles like “Theranos revisited: the trial and lessons learned.”^[1][3] It is a reminder that a story about a single drop of blood grew into a global parable—about innovation, trust, and what happens when the line between vision and truth is crossed.